Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Contracts wins underpin full-year expectations at Kromek

The company believes the DTRA contract represents another major opportunity to adapt its technology base to fit the needs of US military and security personnel working in the field.
Radiation detection
"The frequency and quantum of the contracts are going up,” the CEO said.

Radiation detection technology company Kromek Group PLC (LON:KMK) has bagged six new contracts worth, in aggregate, around US$3.1mln.

The contracts are with new and existing customers, including the US Defense Threat Reduction Agency (DTRA) and the UK Ministry of Defence (MOD), and are expected to be delivered over the next six to 24 months. To put the size of the contracts into context, the company racked up revenue of £8.3mln (US$9.9mln) in the year to the end of April, 2016.

The biggest contract of the batch is a two-year agreement reached with the US DTRA, worth US$1.6mln, to build on, and further enhance, Kromek’s technology platform to develop a tough-as-old-boots high-performance isotope radiation detector capable of use in military and other harsh environments.

The company believes the DTRA contract represents another major opportunity to adapt its technology base to fit the needs of US military and security personnel working in the field.

Elsewhere, two of the remaining five contracts are in the nuclear radiation detection segment. One, worth US$430,000, is with the MOD, while the other, worth US$278,000, represents an extension to an existing contract with a major civil nuclear partner.

The group’s medical division has entered into an agreement, worth a minimum of US$560,000 over two years, for the supply of cadmium zinc telluride (CZT)-based gamma radiation detectors with an existing medical customer.

The final two contracts, worth US$265,000, were snagged by the aviation security division. One was for the company’s bottle scanners, from an Asian airport group that is a new customer, while the other was for components for screening systems from an existing customer; these contracts are expected to be fulfilled over the next six months.

“The contract wins add to the visibility of revenues, underpinning our belief in the continuing growth of the business and commercial traction resulting from the increasing adoption of CZT-based technology,” said Dr Arnab Basu, chief executive officer of Kromek.

Speaking to Proactive Investors, Dr Basu said today’s contracts “are the bedrock of our numbers” and should give the market increased confidence of the company’s ability to meet its targets.

The Kromek CEO said the company had being doing business with the US Department of Defense (DoD) for five or six years now, and the “frequency and quantum of the contracts are going up”.

He ascribed this to two things, the first of which is the relevancy of Kromek’s technology for the modern age. More important, arguably, is the quality of the work Kromek delivers.

“We deliver contracts on time and sometimes ahead of time,” he said, adding that sometimes it had surprised itself and customers, such as DARPA – the US DoD agency that appointed Kromek as sole supplier of personal radiation detection devices – by delivering well ahead of schedule, which does wonders for the company’s credibility.

“There’s a big, exciting story going on here,” he concluded.

--- ADDS CEO COMMENTS ---

View full KMK profile View Profile

Kromek Group PLC Timeline

Related Articles

VW-plant.jpg
October 10 2017
Mike McAuliffe reckons the company's technology is 'tremendous', it is just a case of making the most of it commercially
Tekcapital-Invention-Discovery-Network-(IDN)-June-2015_opt.jpg
July 31 2017
The firm has established connections with more than 4,000 universities in 160 countries enabling it to capture all of the intellectual property available
Runner
January 17 2017
The shares ended 2016 at 8.89p having started it at 3.66p. Backers have consistently exercised warrants to acquire more shares.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use